Google Übersetzer
Incyte Corporation
About
Incyte Corporation (NASDAQ:INCY) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 2 2026
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
Mar 28 2026
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Mar 25 2026
Incyte Announces Executive Leadership Appointments
Mar 20 2026
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Mar 6 2026
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
Recent Videos
INTERVIEW DE CLAIRE DURAND - INCYTE BIOSCIENCES FRANCE
Apr 16, 2026
INCY: Jakafi's Sunset - Can Incyte Survive? (2025 Deep Dive)
Apr 07, 2026
Saturday, April 4, 2026 11AM UTC – Daily News: Police…
Apr 04, 2026
Pharma: Incyte vs. Viatris - Drug Leaders!
Apr 01, 2026
Financials
Revenue
$5.14 B
Market Cap
$19.09 B
P/E Ratio
14.97
EPS
6.41